

## DAFTAR PUSTAKA

- Abdelmabood, S., Fouda, A.E., Boujettif, F. and Mansour, A., 2020. Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. *Jornal de Pediatria*, 96(1), pp.108–116.
- Alcazar, A.M., Enriquez, J.C., Ruiz, C.A.G., Gutierrez, A.F. and Arangure, J.M.M., 2013. Alterations of nutritional status in childhood acute leukemia. *Molecules to the Clinic*, 12, pp.1–21.
- Antillon, F.A., Rossi, E., Molina, A.L., Sala, A., Pencharz, P., Valsecchi, M.G. *et al.*, 2013. Nutritional status of children during treatment for acute lymphoblastic leukemia in Guatemala. *Pediatr Blood Cancer*, 60, pp.911–915.
- Arber, D.A., Orazi, A., Hasserjian, R., Borowitz, M.J., Beau, M.M. Le, Bloomfield, C.D., *et al.*, 2016. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood cancer journal*, 127(20), pp.2391–2406.
- Ariawati, K., Windiastuti, E. and Gatot, D., 2007. Toksisitas kemoterapi leukemia limfoblastik akut pada fase induksi dan profilaksis susunan saraf pusat dengan metotreksat 1 gram. *Sari Pediatri*, 9(4), p.252.
- Basch, E. *et al.*, 2014. Development of the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *Journal of the National Cancer Institute*, 106(9), pp.1–11.
- Beaumais, T.A. De, Fakhoury, M., Medard, Y., Azougagh, S., Zhang, D., Yakouben, K. *et al.*, 2011. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. *British Journal of Clinical Pharmacology*, 71(4), pp.575–584.
- Beek, J.N. Van Der, Oosterom, N., Pieters, R., Jonge, R. De and Heuvel-eibrink, M.M. Van Den, 2019. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review. *Critical Reviews in Oncology / Hematology*, 142(July), pp.1–8.
- Bernardo, M.E., Gordon, P.M. and Masetti, R., 2017. Central nervous system complications in children receiving chemotherapy or hematopoietic stem cell transplantation. *Frontiers in Pediatrics*, 5(May), pp.1–15.
- Biswal, S. and Godnaik, C., 2013. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. *Ecancer.*, 7, pp.1–16.

- Booth, T.J., Pizzocchero, F., Andersen, H., Hansen, T.W., Wagner, J.B., Jinschek, J.R., *et al.*, 2017. *In-situ observation of discrete gasification of carbon in suspended graphene by silver nanoparticles*,
- Brunton, L., Chabner, B. and Knollman, B., 2011. *Goodman&Gilman's: The pharmacological basis of therapeutics* 12th Editi., New York: Mc Grawhills.
- Byrnes, D.M., Vargas, F., Dermarkarian, C., Kahn, R., Kwon, D., Hurley, J., *et al.*, 2019. Complications of intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients. *Journal of Oncology*, 2019, pp.1–8.
- Caneba, J.P., Estanislao, J., Fajardo, P., Lam, C. and Alcasabas, A.P., 2017. Improved outcomes in pediatric acute lymphoblastic leukemia (ALL) with adapted treatment intensity: The use of SIOP-PODC ALL regimen 2 in a resource-limited tertiary referral setting. *Blood Advances*, 1(12), pp.46–48.
- Carroll, W.L., Bhojwani, D., Min, D., Raetz, E., Relling, M., Davies, S., *et al.*, 2003. Pediatric Acute Lymphoblastic Leukemia. *American Society of Hematology*, pp.102–131.
- Ceppi, F., Antillon, F., Pacheco, C., Sullivan, C.E., Lam, C.G., Howard, S.C. *et al.*, 2015. Supportive medical care for children with acute lymphoblastic leukemia in low-and middle-income countries. *Expert Review of Hematology*, 8(5), pp.613–626.
- Ceppi, F., Cazzaniga, G., Colombini, A., Biondi, A. and Conter, V., 2015. Risk factors for relapse in childhood acute lymphoblastic leukemia: Prediction and prevention. *Expert Review of Hematology*, 8(1), pp.57–70.
- Chaudhary, S. and Mittra, I., 2019. Cell-free chromatin: A newly described mediator of systemic inflammation. *Journal of Biosciences*, 44(2), pp.1–6.
- Chiaretti, S., Zini, G. and Bassan, R., 2014. Diagnosis and subclassification of acute lymphoblastic leukemia. *Mediterr J hematol infec dis*, 6(October), pp.1–14.
- Conway, R. and Carey, J.J., 2017. Risk of liver disease in methotrexate treated patients. *World J Hepatol*, 26(September), pp.1092–1100.
- Cyriac, S., Rajendranath, R. and Sagar, T.G., 2008. Early CNS toxicity after intrathecal methotrexate. *Indian Journal of Hematology and Blood Transfusion*, 24(4), pp.186–187.
- Douer, D., 2016. Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. *The Oncologist*, 21(7), pp.840–847.

- Fernández-ramos, A.A., Marchetti-laurent, C. and Poindessous, V., 2017. 6-mercaptopurine promotes energetic failure in proliferating T cells. *Oncotarget*, 8(26), pp.43048–43060.
- Giovannetti, E., Ugrasena, D.G., Supriyadi, E., Vroling, L., Azzarello, A., de Lange, D. *et al*, 2008. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. *Leukemia Research*, 32, pp.19–24.
- Gupta, S., Antillon, F.A., Sung, L., Howard, S.C., Fu, L., Bonilla, M., *et al.*, 2011. Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. *Cancer*, 117(20), pp.4788–4795.
- Gupta, S., Bonnila, M., Fuentes, S., Caniza, M., Howard, S., Barr, R., *et al.*, 2009. Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. *British Journal of Cancer*, 100(7), pp.1026–31.
- Hafidhaturrahmah, Supriyadi, E. and Nurani, N., 2019. Pengaruh status gizi terhadap kesintasan pada anak leukemia limfoblastik akut di RSUP Dr Sardjito. Thesis, Universitas Gadjah Mada.
- Herintya, F., Mulatsih, S. and Prawirohartono, E.P., 2008. Association between nutritional status and outcome of childhood acute lymphoblastic leukemia treated with Wijaya Kusuma Protocol. *Paediatrica Indonesiana*, 48(1), p.28.
- Howard, S.C., McCormick, J., Pui, C.H., Buddington, R.K. and Harvey, D., 2016. Preventing and managing toxicities of high-dose methotrexate. *The Oncologist*, 21(8), pp.1–12.
- Hunger, S.P., Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J., *et al.*, 2012. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group. *Journal of Clinical Oncology*, 30(14), pp.1663–1669.
- Jacob, L.A., Sreevatsa, A., Chinnagiriappa, L.K., Dasappa, L., Suresh, T.M. and Babu, G., 2015. Methotrexate-induced chemical meningitis in patients with acute lymphoblastic leukemia / lymphoma. *Annals of Indian Academy of Neurology*, 18(2), pp.206–210.
- Jayachandran, D., Rundell, A.E., Hannemann, R.E., Vik, T.A. and Ramkrishna, D., 2014. Optimal chemotherapy for leukemia: A model-based strategy for individualized treatment. *Plos one*, 9(10), pp.1–18.

- Kato, M. and Manabe, A., 2018. Treatment and biology of pediatric acute lymphoblastic leukemia. *Pediatrics international*, 60(November), pp.4–12.
- Kroll, M., Kaupat-Bleckmann, K., Möricke, A., Alten, J., Schewe, D.M., Stanulla, M., *et al.*, 2019. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. *Haematologica*, pp.1–33.
- Kumar, A.J. *et al.*, 2016. Delays in post-remission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: an analysis from ECOG 2993/MRC UK ALLXII. *American Journal of Hematology*, 91(11), pp.1107–1112.
- Lanzkowsky, P., Lipton, J.M. and Fish, J.D., 2016. *Lanzkowsky's manual of pediatric hematology and oncology sixth edition*,
- Lee, J.W. and Cho, B., 2017. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. *Korean J Pediatr*, 60(April), pp.129–137.
- Levine, S.R., Mcneer, J.L. and Isakoff, M.S., 2016. Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults. *Clinical Oncology in Adolescents and Young Adults.*, 6, pp.11–20.
- Løhmann, D.J.A., Abrahamsson, J., Ha, S., Jónsson, Ó.G., Koskenvuo, M., Lausen, B., Palle, J., *et al.*, 2016. Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. *Haematologica*, 101(11), pp.1359–1367.
- Lund, B. *et al.*, 2010. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. *Pediatr Blood Cancer*, 56(May), pp.551–559.
- Machin, D., Campbell, M.J., Tan, S.B. and Tan, S.H., 2009. *Sample size tables for clinical studies third edition*, Hong Kong: Wiley-Blackwell.
- Meeske, K.A. *et al.*, 2015. Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: A report from the children's oncology group. *Pediatr Blood Cancer*, 62(12), pp.2140–2149.
- Meshinchi, S. and Arceci, R., 2007. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. *The Oncologist*, 12(January), pp.341–355.
- Mittra, I. *et al.*, 2017. Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. *Annals of Oncology*, 28(9), pp.2119–2127.

- Mulatsih, S. and Meiliana, S., 2017. Leukemia limfoblastik akut pada anak usia di bawah satu tahun. *Sari Pediatri*, 11(3), p.219.
- Oskarsson, T., Söderhäll, S., Arvidson, J., Forestier, E., Bottai, M., Lausen, B. *et al*, N., 2016. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries : prognostic factors, treatment and outcome. *Hematologica*, 101(1), pp.68–76.
- Ozdemir, Z.C., Turhan, A.B. and Bor, O., 2016. The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate. *International Journal of Pediatrics & Adolescent Medicine*, 3(4), pp.162–168.
- Parvareh, M., Khanjani, N., Farahmandinia, Z. and Nouri, B., 2015. The survival of childhood leukemia and its related risk factors in Kerman, Iran. *Iranian Journal of Health Sciences*, 3(December), pp.24–32.
- Permatasari, E., Windiastuti, E. and Satari, H.I., 2009. Survival and prognostic factors of childhood acute lymphoblastic leukemia. *Paediatrica Indonesiana*, 49(6), pp.365–371.
- Pui, C., Robison, L.L. and Look, A.T., 2008. Acute lymphoblastic leukaemia. *Lancet*, 371(Maret), pp.1030–1043.
- Ribeiro, M.P.C., Santos, A.E.C. and Custodio, J.B.A., 2015. Mitochondrial dysfunction on the toxic effects of anticancer agents - from lab bench to bedside. *Toxicology studies*, pp.1–39.
- Riskesdas., 2013. *Penderita kanker leukemia di Yogyakarta*,
- Rivera, G.K. and Ribeiro, R.C., 2014. Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships. *Expert Review of Hematology*, 7(5), pp.649–657.
- Rudin, S., Marable, M. and Huang, R.S., 2017. The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. *Genomics, Proteomics & Bioinformatics*, 15(2), pp.82–93.
- Rujkijyanont, P., Kaewinsang, S., Monsereenusorn, C. and Traivaree, C., 2014. Pediatric acute leukemia : The effect of prognostic factors on clinical outcomes at Phramongkutklao Hospital, Bangkok, Thailand. *J Med Assoc Thai*, 97(2), pp.188–195.
- Schmiegelow, K., 2009. Advances in individual prediction of methotrexate toxicity : a review. *British Journal of Haematology*, 146, pp.489–503.

- Schmiegelow, K., Levinsen, M.F., Attarbaschi, A., Baruchel, A. and Devidas, M., 2013. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, 31(19), pp.2469–2475.
- Shull, S., 2016. High-dose methotrexate, leucovorin and glucarpidase dosing, administration, and monitoring-adult/pediatric-inpatient clinical practice guideline. , pp.1–15.
- Simanjorang, C., Kodim, N. and Tehuteru, E.S., 2013. Perbedaan kesintasan 5 tahun pasien leukemia limfoblastik akut dan leukemia mieloblastik akut pada anak di Rumah Sakit Kanker Dharmais. *Indonesian Journal of Cancer*, 7(1), pp.15–21.
- Solomon, B., Parihar, N., Ayodele, L. and Hughes, M., 2017. Global incidence and prevalence of acute lymphoblastic leukemia : A 10-year forecast. *J Blood Disord Transfus*, 08(05), p.9864.
- de Sousa, D.W., de Almeida, F., Felix, F. and de Oliveira, M., 2015. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. *Rev Bras Hematol Hemoter*, 37(4), pp.223–229.
- Sary, J. *et al.*, 2014. Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002. *Journal of Clinical Oncology*, 32(3), pp.174–184.
- Sutaryo, Mulatsih, S. and Setiawan, S., 2017. *Manual obat sitostatika injeksi*, Yogyakarta: Best Publisher.
- Tahura, S. and Hussain, M., 2017. Treatment refusal and abandonment in pediatric patients with acute lymphoblastic leukemia in Bangladesh. *International Journal of Science and Research (IJSR)*, 6(8), pp.643–645.
- Terwilliger, T. and Abdul-Hay, M., 2017. Acute lymphoblastic leukemia : a comprehensive review and 2017 update. *Blood cancer journal*, 7(March), pp.1–12.
- Traivaree, C., Likasitthananon, N., Monsereenusorn, C. and Rujkijyanont, P., 2018. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients. *Cancer Management and Research*, Volume 10, pp.4471–4478.
- Vagace, J.M. and Gervasini, G., 2011. Chemotherapy toxicity in patients with acute leukemia. , pp.1–26.



- Vaitkeviciene, G., Matuzeviciene, R., Stoskus, M., Zvirblis, T., Rageliene, L. and Schmiegelow, K., 2014. Cure rates of childhood acute lymphoblastic leukemia in Lithuania and the benefit of joining international treatment protocol. *Medicina (Lithuania)*, 50(1), pp.28–36.
- Varghese, B., Joobomary, A. and Savida, P., 2018. Five - year survival rate and the factors for risk - directed therapy in acute lymphoblastic leukemia. *Indian Journal of Medical and Pediatric Oncology*, 39(October), pp.301–306.
- Vlierberghe, P. Van, Ferrando, A., Vlierberghe, P. Van and Ferrando, A., 2012. The molecular basis of T cell acute lymphoblastic leukemia Find the latest version : Review series The molecular basis of T cell acute lymphoblastic leukemia. *The Journal of Clinical Investigation*, 122(10), pp.3398–3406.
- Wiczer, T., Dotson, E., Tuten, A., Phillips, G. and Maddocks, K., 2016. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. *Journal of Oncology Pharmacy Practice*, 22(3), pp.430–436.
- Widiaskara, I., Permono, B., Ugrasena, I. and Ratwita, M., 2010. Luaran pengobatan fase induksi pasien leukemia limfoblastik akut pada anak di Rumah Sakit Umum Dr. Soetomo Surabaya. *Sari Pediatri*, 12(2), pp.128–34.
- Widiretnani, S., Mulatsih, S. and Julia, M., 2019. Pengaruh toksisitas kemoterapi fase induksi terhadap kesintasan anak dengan leukemia limfoblastik akut di RSUP Dr. Sardjito Yogyakarta. Thesis, Universitas Gadjah Mada.
- Widnyana, A.A.N.K.P., 2015. Angka kesintasan dan faktor yang memengaruhi pasien leukemia limfoblastik akut pada anak di RS Sanglah tahun 2010-2012. , pp.1–38.
- Wijayanti, L.P. and Supriyadi, E., 2017. Faktor prognostik dan kesintasan pasien leukemia limfoblastik akut anak di RSUP Dr. Sardjito, Yogyakarta, 2010–2015. *Indonesian Journal of Cancer*, 11(4), pp.145–150.
- Yang, X. *et al.*, 2016. Complications and outcomes of pediatric patients with hyperleukocytic acute lymphoblastic leukemia with CCLG-2008 protocol. *Int J Clin Exp Med*, 9(2), pp.3324–3333.
- Zangoeei, R., Hedayati, A.A., Vossough, P., Mehrvar, A., Golpayegani, M., Yazdi, F. *et al.*, 2012. Medium and high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia. *Iranian Journal of Blood and Cancer*, 5(1), pp.19–23.

- Zawitkowska, J., Lejman, M., Zaucha-Prazmo, A., Drabko, K., Płonowski, M., Bulsa, J., *et al.*, 2019. Grade 3 and 4 toxicity profiles during therapy of childhood acute lymphoblastic leukemia. *In vivo*, 33(April), pp.1333–1339.
- Zhang, S., Liang, F. and Tannock, I., 2016. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. *Biomed central*, 16(392), pp.1–6.
- Zhang, X., Rastogi, P., Shah, B. and Zhang, L., 2017. B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations , subclassification and targeted therapy. *Oncotarget*, 8(39), pp.66728–66741.